A comparative study of treatment modalities in female androgenetic alopecia
DOI:
https://doi.org/10.18203/2320-6012.ijrms20160815Keywords:
AGA, Minoxidil, PRP, Female, Hair lossAbstract
Background: Androgenetic alopecia (AGA) occurs in both men and women. It is characterized by progressive loss of hair from the scalp in a defined pattern. The aim of the study was to analyse and assess the efficacy of treatment modalities in female androgenetic alopecia (AGA) and assess the side effects, level of stress, associated family history and past history of any medical illness in these patients.
Methods: 60 female patients between 18-50 years of age were randomly divided into 2 groups, with 30 cases in each. The first group (Group A), received only topical 2% minoxidil, applied in the form of a 1 ml solution at an interval of 12 hours and the second group (Group B), received combination of 2% minoxidil and platelet rich plasma (PRP) therapy injections every 15 days for 2 months and then every monthly for 4 months. Patients were evaluated every 2 months for a period of 6 months based on patient and physician assessment of clinical improvement, photographic evidence and type of hair growth. Side effects during the treatment period were observed for.
Results: 70% (n=42) of patients were in the age group 18-30 years. 56.67% (n=34) had alopecia of Ludwig pattern type 2. Hypothyroidism was the major associated medical illness seen in 20% (n=20) of patients. Family history was seen in 46.66% (n=28). 73.33% (n=44) had stress in the range of 5-7 on a visual analogue scale (VAS) of 10. Excellent improvement was observed in 33.33% of patients of Group A (Minoxidil only), and in 60% (n=36) of patients of Group B (Minoxidil + PRP). Pruritis was the most common side effect seen in 13.33% (n=8) patients.
Conclusions: Non-invasive management for AGA is a safe, effective and promising tool for hair growth. It offers better patient compliance, less side effects and only topical anesthesia is required. Multimodality approach in the treatment of hair loss gives excellent response, which is seen in our study as combination therapy (2% minoxidil with PRP) is more effective than topical minoxidil alone.
References
Ellis JA, Sinclair R, Harrap SB. Androgenetic alopecia: pathogenesis and potential for therapy. Expert Rev Mol Med. 2002;4(22):1-11.
Yip L, Zaloumis S, Irwin D. Gene-wide association study between the aromatase gene (CYP19A1) and female pattern hair loss. Br J Dermatol. 2009;161:289-94.
Simpson N, Barth J. Hair patterns: hirsuties and baldness In: Rook A, Dawber R (eds). Diseases of the Hair and Scalp, 3rd edn. Oxford: Blackwell Scientific. 1997:67-122.
Justine A. Ellis, Rodney Sinclair and Stephen B. Harrap. Androgenetic alopecia: pathogenesis and potential for therapy. Exp. Rev. Mol. Med. 19 November, http://www.expertreviews.org/ 02005112h.htm.
Rinaldi F, Sorbellini E, Coscera T. The Role of Platelet Rich Plasma to control anagen phase: Evaluation in vitro & in vivo in Hair Transplant and Hair Treatment. Int J Trichol. 2011;3.
Parsley WM, Perez-Meza D. Review of Factors Affecting the Growth and Survival of Follicular Grafts. J Cutan Aesthet Surgery. 2010;3(2):69-75.
Li ZJ, Choi HI, Choi DK. Autologous platelet-rich plasma: a potential therapeutic tool for promoting hair growth. Dermatol Surg. 2012;38(7 Pt 1):1040-6.
Reese RJ. Autologous Platelet Rich Plasma: What do we know? Important concepts relevant to Hair Restoration Surgery. Hair Transplant Forum Intl 2010;20(1):14-17.
Zhuang, Xiao-Sheng. Quality of life in women with female pattern hair loss and the impact of topical minoxidil treatment on quality of life in these patients. Age (years). 2013;32:10-351.
Han, Sung-Hyub. Quality of life assessment in male patients with androgenetic alopecia: result of a prospective, multicenter study. Annals of Dermatology. 2012;24,3:311-8.
Xiao-Sheng Z. You-You Z, Jia-Jia X. Quality of life in women with female pattern hair loss and the impact of topical minoxidil treatment on quality of life in these patients Exp Ther Med. 2013;6(2):542-6.
Sullivan JR, Steven K. Acquired scalp alopecia. Part II: A review. Australasian journal of dermatology. 1999;40(2):61-72.
Zhang X, Caulloo S, Zhao Y. Female pattern hair loss: Clinico-laboratory findings and trichoscopy depending on disease severity. Int J Trichol. 2012;4:23-8.
Xingqi Z, Sillani C, Ying Z. Int J Trichology. 2012;4(1):23-8.
Ryoji T, Takao T, Tooru N. A randomized, placebo-controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. Eur J Dermatol. 2007;17(1):37-44.
O’Driscoll JB, Mamtora H, Higginson J, Pollock A, Kane J, Anderson DC.. A prospective study of the prevalence of clear-cut endocrine disorders and polycystic ovaries in 350 patients presenting with hirsutism or androgenetic alopecia. Clin Endocrino. 1994;41(2):231-6.
DeVillez RL, Jacobs JP, Szpunar CA. Androgenetic Alopecia in the Female Treatment With 2% Topical Minoxidil Solution. Arch Dermatol. 1994;130(3):303-7.
Evelyn-Evanthia B, Esnault G, Kalbermatten DF, Mathias T. Veronique Emmenegger Platelet-rich plasma injection is effective and safe for the treatment of alopecia European Journal of Plastic Surgery. 2013;36(7):407-12.
